Background To assess the response rate, toxicity and survival in patients with malignant pleural mesothelioma treated with liposomal daunorubicin. The study design allowed for dose escalation pending toxicity
Introduction
The incidence of malignant pleural mesothelioma is predicted to increase by a factor of three in the next 20 years in many industrialised societies [1] . This reflects the increasing use of asbestos without adequate precautions until the early 1970s and the latent period of around 40 years between first exposure to asbestos and development of the disease.
Malignant pleural mesothelioma is considered resistant to all forms of treatment Surgical series have reported encouraging survival figures with extrapleural pneumonectomy combined with chemotherapy and radiotherapy [2] , though few patients are suitable for this approach. Similarly, the role of chemotherapy is uncertain. Few drugs produce sustained responses though response rates of between 10% and 20% are seen with several agents [3] . Anthracychnes have been shown to have some activity against mesothelioma. A recent review stated that doxorubicin gives a response rate of 15%-20% [4] No data exists on the sister drug daunorubicin but the review authors considered that further trials with anthracyclines would be of value.
Liposomal daunorubicin (DaunoXome, Nexstar, USA) consists of daunorubicin citrate in a unilamellar liposomal carrier system. Studies have shown that hposomes of this type result in a selectively high accumulation of hposome contents in the tumour [5] Initial phase I data showed that the maximum tolerated dose of liposomal daunorubicin was 100-120 mg/m 2 with the dose limiting toxicity being myelosuppression [6] Other anthracycline-associated toxicities such as cardiotoxicity were rare
Patients and methods

Eligibility
All patients had histologically-confirmed malignant pleural mesothelioma All biopsies were reviewed centrally by an expert panel of specialist oncology pathologists A panel of immunohistochemical stains was used in all cases Other inclusion criteria were measurable disease, no prior chemotherapy or radiotherapy, age > 18 years, performance status (ECOG) 00-2. adequate haemalological reserve WBC >4 x 10 9 /l, platelets > 100 x IO 9 /I, Hb > 10 g/dl. able to give written informed consent The study had appropriate institutional ethical review board approval
Treatment
Liposomal daunorubicin was administered al 120 mg/m" intravenously each 21 days until disease progression or unacceptable loxicity Appropriate dose modifications were made for major toxicities CT chest scans were performed pre-treatment and after each two cycles then three-monthly on follow-up The study design allowed for dose escalation in increments of 20 mg/m 2 though no dose increases were possible because of toxicity experienced at the first dose level
Toxicity and endpoints
Toxicities were recorded according to ECOG criteria Major endpoints were response rate, toxicity and survival
Results
Patient characteristics, clinical response and survival
Fourteen patients were enrolled (characteristics are shown in Table 1 ) All patients presented a clear history of exposure to asbestos. There were no complete or partial responses Nine patients (64%) were assessed as stable disease at first assessment after two cycles of hposomal daunorubicin Of these nine patients, five received the full six cycles of chemotherapy, one patient stopped after two cycles due to worsening angina, one patient stopped after three cycles due to extreme malaise, one patient stopped after four cycles due to malaise, and one patient stopped after five cycles due to recurrent neutropeniarelated infection Five patients (36%) progressed on therapy The median duration of stable disease from first treatment for patients not progressing on therapy was 5 1 months The median overall survival for all patients from first treatment was 6 1 months.
Toxicities
Toxicity was significant, three patients received less than three cycles of chemotherapy (one patient died of mesothehoma after one cycle, one patient progressed after one cycle and one patient experienced angina on chemotherapy). Of the 11 remaining patients, 9 (64%) had grade 3 or 4 neutropenia on at least one occasion and 4 patients had at least 1 episode of grade 3 or 4 infection. Grade 3 or 4 malaise occurred in five patients. Grade 1 or 2 nausea and vomiting occurred at least once in all patients. The median number of chemotherapy cycles administered per patient was 4 5 (range 1-6)
Discussion
Liposomal daunorubicin does not appear to have useful activity against malignant pleural mesothehoma and toxicity was significant with grade 3 or 4 neutropenia occurring in most patients Four patients required hospital admission for intravenous antibiotics and fluid resuscitation. The dose used in this trial (120 mg/m 2 every 21 days) would appear to be the maximum tolerated dose in this group of patients with neutropenia being the dose-limiting toxicity.
Our data are consistent with existing phase I data which have shown that liposomal daunorubicin at a dose of 100 mg/m 2 repeated three-weekly is feasible with myelosuppression limiting further dose escalation [6] Liposomal daunorubicin has been widely reported as a treatment for HIV-associated Kaposi's sarcoma. The most common schedule for patients with Kaposi's sarcoma is 40-60 mg/m 2 of liposomal daunorubicin every 14 days [7] As with the 21-day schedule described in the current study, myelosuppression is the major side effect and other anthracychne-associated toxicities such as nausea, hair loss and cardiomyopathy are not seen. Recently, liposomal daunorubicin at a dose of 120 mg/m 2 every three weeks has been reported in relapsed lymphomas with acceptable toxicity and some clinical benefit [8] .
Liposomal daunorubicin and other liposomallyencapsulated drugs are being investigated in many diseases Liposomally-encapsulated drugs are indicated for patients with HIV-related Kaposi's sarcoma, ovarian and breast cancer. Liposomal daunorubicin at a dose of 120 mg/m 2 every three weeks has no useful clinical activity in malignant pleural mesothelioma
